early stage ER/PR+/HER-2−, late stage ER/PR+/HER-2−, Early stage ER/PR−/HER-2+, early stage triple-negative breast cancer (TNBC), and late stage TNBC using tumor and normal adjacent tissue (NAT) samples. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.